Literature DB >> 8107215

Functional analysis of N-linked glycosylation mutants of the measles virus fusion protein synthesized by recombinant vaccinia virus vectors.

G Alkhatib1, S H Shen, D Briedis, C Richardson, B Massie, R Weinberg, D Smith, J Taylor, E Paoletti, J Roder.   

Abstract

The role of N-linked glycosylation in the biological activity of the measles virus (MV) fusion (F) protein was analyzed by expressing glycosylation mutants with recombinant vaccinia virus vectors. There are three potential N-linked glycosylation sites located on the F2 subunit polypeptide of MV F, at asparagine residues 29, 61, and 67. Each of the three potential glycosylation sites was mutated separately as well as in combination with the other sites. Expression of mutant proteins in mammalian cells showed that all three sites are used for the addition of N-linked oligosaccharides. Cell surface expression of mutant proteins was reduced by 50% relative to the wild-type level when glycosylation at either Asn-29 or Asn-61 was abolished. Despite the similar levels of cell surface expression, the Asn-29 and Asn-61 mutant proteins had different biological activities. While the Asn-61 mutant was capable of inducing syncytium formation, the Asn-29 mutant protein did not exhibit any significant cell fusion activity. Inactivation of the Asn-67 glycosylation site also reduced cell surface transport of mutant protein but had little effect on its ability to cause cell fusion. However, when the Asn-67 mutation was combined with mutations at either of the other two sites, cleavage-dependent activation, cell surface expression, and cell fusion activity were completely abolished. Our data show that the loss of N-linked oligosaccharides markedly impaired the proteolytic cleavage, stability, and biological activity of the MV F protein. The oligosaccharide side chains in MV F are thus essential for optimum conformation of the extracellular F2 subunit that is presumed to bind cellular membranes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107215      PMCID: PMC236609     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Two disulfide-linked polypeptide chains constitute the active F protein of paramyxoviruses.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1977-07-01       Impact factor: 3.616

2.  Ability of the hydrophobic fusion-related external domain of a paramyxovirus F protein to act as a membrane anchor.

Authors:  R G Paterson; R A Lamb
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Amino acid sequences in the alpha 1 domain and not glycosylation are important in HLA-A2/beta 2-microglobulin association and cell surface expression.

Authors:  J Santos-Aguado; P A Biro; U Fuhrmann; J L Strominger; J A Barbosa
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

Review 5.  Carbohydrate moieties of glycoproteins. A re-evaluation of their function.

Authors:  K Olden; J B Parent; S L White
Journal:  Biochim Biophys Acta       Date:  1982-05-12

Review 6.  The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses.

Authors:  P W Choppin; A Scheid
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

7.  Measles virus polypeptides synthesis in infected cells.

Authors:  M C Graves; S M Silver; P W Choppin
Journal:  Virology       Date:  1978-05-01       Impact factor: 3.616

8.  Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence.

Authors:  K L Deshpande; V A Fried; M Ando; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Tunicamycin inhibits glycosylation and multiplication of Sindbis and vesicular stomatitis viruses.

Authors:  R Leavitt; S Schlesinger; S Kornfeld
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

View more
  7 in total

1.  Sequence analysis and expression of the attachment and fusion proteins of canine distemper virus wild-type strain A75/17.

Authors:  P Cherpillod; K Beck; A Zurbriggen; R Wittek
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

2.  N-linked glycans with similar location in the fusion protein head modulate paramyxovirus fusion.

Authors:  Veronika von Messling; Roberto Cattaneo
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.

Authors:  S Bagai; R A Lamb
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus.

Authors:  M Watanabe; A Hirano; S Stenglein; J Nelson; G Thomas; T C Wong
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

5.  Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation.

Authors:  G Alkhatib; J Roder; C Richardson; D Briedis; R Weinberg; D Smith; J Taylor; E Paoletti; S H Shen
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

6.  Functional and structural interactions between measles virus hemagglutinin and CD46.

Authors:  O Nussbaum; C C Broder; B Moss; L B Stern; S Rozenblatt; E A Berger
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

7.  Addicted to sugar: roles of glycans in the order Mononegavirales.

Authors:  Victoria Ortega; Jacquelyn A Stone; Erik M Contreras; Ronald M Iorio; Hector C Aguilar
Journal:  Glycobiology       Date:  2019-01-01       Impact factor: 4.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.